part of his scalp, as well as several squamous cell carcinomas and basal cell carcinomas, which were treated by surgery. The AKs had been treated on numerous occasions with cryotherapy. According to the patient, imiquimod had also been tried, but with little significant effect. We were initially surprised by the notion of lack of success of imiquimod. We, therefore, conducted a new set of applications of imiquimod 5%, once daily for 12 days. To our surprise, there was no noticeable erythema or other sign of inflammation, even after 12 days of continuous application. This lack of inflammatory/immune response probably explains the lack of improvement of the AK he had previously observed. Taking a second look at the patient history, with a special accent on his immune function, we realized that the patient had chronic lymphocytic leukemia (CLL). We deduced that this could account for the lack of response to imiquimod, despite reports that this treatment is efficient in immune-deficient patients [1] [2] [3] [4] .
Gaide/Clayton/Girardin/Kuonen Dermatology 2016;232(suppl 1):7-8 DOI: 10.1159/000447388 8 was much better, and using ingenol mebutate 500 at regular intervals of 6 months has allowed us to stabilize the scalp situation, with a net decrease in the number of SCC excision on the scalp.
The CLL slowly worsened during the few past years, prompting our patient's hemato-oncologist to start chemotherapy. The patient has responded well to this therapy, and we now hope that the increased function of his immune system will better keep AKs under control and favor a more prolonged response.
Discussion
In summary, we report the case of a patient responding neither to 5-FU nor imiquimod nor daylight PDT and not tolerating conventional PDT either, but who responded well to a maximized regimen of 500 μg/g ingenol mebutate as an off-label treatment. We think that ingenol mebutate can be a useful option for dermatologists dealing with slightly immune-compromised patients.
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